Skip to content

Clinical Study on the Influencing Factors and Prognosis of Left Ventricular Reverse Remodeling in Patients with Heart Failure with Reduced Ejection Fraction

Clinical Study on the Influencing Factors and Prognosis of Left Ventricular Reverse Remodeling in Patients with Heart Failure with Reduced Ejection Fraction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093504
Enrollment
Unknown
Registered
2024-12-06
Start date
2024-12-10
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Left ventricular inverse remodeling group:None
Left ventricular retrograde remodeling did not occur in the group:None

Sponsors

The Fifth Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Heart failure with reduced ejection fraction was first diagnosed in our hospital from January 2016 ~ November 2023, which was defined as left ventricular ejection fraction <=40%; (2) At least two visits to our hospital after the first diagnosis of heart failure with reduced ejection fraction, including but not limited to outpatient and inpatient departments; (3) The management of the professional team provides guideline-oriented standardized drug treatment, in which ARNI/ACEI/ARB and ß-B need to be individually titrated to the maximum tolerated dose every 1 ~ 2 weeks according to the patient's tolerance, symptoms, signs, and laboratory indicators. Patients receive device therapy as needed, including implantable transvenous cardioverter defibrillators, fully subcutaneous implantable cardioverter defibrillators, and cardiac resynchronization therapy pacemakers/cardioverter defibrillators.

Exclusion criteria

Exclusion criteria: (1) Severe hepatic and renal insufficiency, defined as serum creatinine > 221 µmol/L, liver function Child-Pugh grade C; (2) postoperative CRT or CRT-D; inoperable aortic valve heart disease; Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) expected within 6 months or within 3 months; (3) life expectancy of < 1 year due to causes other than heart failure, such as advanced cancer; (4) after heart transplantation; (5) Severe obstructive or restrictive pulmonary disease; (6) Autoimmune diseases and acute and chronic infectious diseases; (7) Patients with self-limiting cardiomyopathy, such as cardiomyopathy caused by tachycardia, perinatal cardiomyopathy, myocarditis, and alcoholic cardiomyopathy.

Design outcomes

Primary

MeasureTime frame
Left ventricular end-diastolic diameter index;Left ventricular ejection fraction;Left ventricular end-systolic diameter;

Countries

China

Contacts

Public ContactShao Mengjiao

The Fifth Affiliated Hospital of Sun Yat-sen University

shaomj0304@126.com+86 181 3868 0304

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026